Ligand to Participate in September Investor Conferences
Rhea-AI Summary
Ligand (Nasdaq: LGND) reported that its senior management will participate in three investor events in September 2026: Wells Fargo Healthcare Conference in Boston on September 8 at 12:45 p.m. ET, Citi 2026 Biopharma Back to School Conference in New York on September 10 at 9:20 a.m. ET, and H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14 at 10:00 a.m. ET. Management also plans to hold one-on-one meetings with investors and attendees during these conferences.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Q2 results update | Neutral | -2.4% | Q2 results included cash, strategic capital, trial progress, and net loss. |
| Aug 06 | Q2 earnings report | Positive | -0.8% | Q2 revenue and earnings growth, notes offering, acquisition, and raised EPS floor. |
| Jul 23 | Earnings date notice | Neutral | -0.7% | Scheduled Q2 results release and conference call for August 6. |
| Jul 14 | Royalty acquisition | Positive | -2.7% | Completed XOMA Royalty acquisition for cash plus contingent value right. |
| Jun 25 | Notes offering | Neutral | +2.6% | Closed 0.00% convertible senior notes offering, including option exercise. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Ligand earnings, scheduling, and acquisition announcements were followed by negative reactions, while the convertible notes offering was followed by a positive reaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences:
- Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.
- Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.
- H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Wells Fargo, Citi, or H.C. Wainwright representative.
About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
This press release was published by a CLEAR® Verified individual.
